home / stock / bovnf / bovnf quote
Last: | $4.70 |
---|---|
Change Percent: | 100.0% |
Open: | $0 |
Close: | $4.70 |
High: | $0 |
Low: | $0 |
Volume: | 14 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$4.7 | $0 | $4.7 | $0 | $0 | 14 | 02-08-2023 |
$4.7 | $0 | $4.7 | $0 | $0 | 80 | 01-24-2023 |
$4.7 | $4.7 | $4.7 | $4.7 | $4.7 | 908 | 07-29-2022 |
$5.49 | $5.49 | $5.49 | $5.49 | $5.49 | 100 | 12-21-2021 |
$5.25 | $5.25 | $5.25 | $5.25 | $5.25 | 1,000 | 12-16-2021 |
$5.25 | $5.25 | $5.25 | $5.25 | $5.25 | 1,000 | 12-10-2021 |
$5.38 | $5.38 | $5.38 | $5.38 | $5.38 | 3,000 | 09-07-2021 |
$6.84 | $6.84 | $6.84 | $6.84 | $6.84 | 600 | 06-29-2021 |
$5.6 | $5.6 | $5.6 | $5.6 | $5.6 | 100 | 03-18-2021 |
$0.2 | $0.2 | $0.2 | $0.2 | $0.2 | 2,500 | 12-09-2020 |
$0.1847 | $0.1847 | $0.1847 | $0.1847 | $0.1847 | 25,000 | 07-21-2020 |
$ | $N/A | $0.14 | $N/A | $N/A | 0 | 02-12-2020 |
$ | $N/A | $0.14 | $N/A | $N/A | 0 | 02-11-2020 |
$ | $N/A | $0.14 | $N/A | $N/A | 0 | 02-10-2020 |
$ | $N/A | $0.14 | $N/A | $N/A | 0 | 02-07-2020 |
$ | $N/A | $0.14 | $N/A | $N/A | 0 | 02-06-2020 |
$ | $N/A | $0.14 | $N/A | $N/A | 0 | 02-05-2020 |
$ | $N/A | $0.14 | $N/A | $N/A | 0 | 02-04-2020 |
$ | $N/A | $0.14 | $N/A | $N/A | 0 | 02-03-2020 |
$ | $N/A | $0.14 | $N/A | $N/A | 0 | 01-31-2020 |
News, Short Squeeze, Breakout and More Instantly...
LUND, SWEDEN / ACCESSWIRE / July 22, 2024 / BioInvent International (STO:BINV) Two posters to be presented on early clinical projects from BioInvent's robust pipeline totaling six clinical programs: Progress with the Phase 1 trial studying BI-1910 as single agent in solid tumors Initial...
LUND, SE / ACCESSWIRE / July 17, 2024 / BioInvent International (STO:BINV) Agreement to support expansion of BI-1607 program with new Phase 2 triplet combination study in metastatic melanoma The study will evaluate anti-FcγRIIB antibody BI-1607 with low-dose anti-CTLA-4, ipilimu...
Model-informed approach supporting dose selection and optimization of clinical development Confirming wide potential dose-range of BI-1808 in the continued clinical evaluation which already has shown promising single agent safety and efficacy Poster to be presented at PAGE 2024 to be ...